According to Zacks, “Transcat, Inc. distributes test and measurement instruments and provides accredited calibration services to a variety of industries including life sciences, pharmaceutical, petroleum refining, chemical manufacturing, public utility, pulp and paper, communications, automotive and aerospace. “
Several other brokerages also recently issued reports on TRNS. Craig Hallum assumed coverage on Transcat in a research note on Thursday, July 16th. They set a buy rating and a $36.00 target price on the stock. B. Riley assumed coverage on Transcat in a report on Wednesday, July 22nd. They set a buy rating and a $35.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Transcat currently has a consensus rating of Buy and a consensus price target of $36.25.
Shares of TRNS opened at $27.90 on Wednesday. The business’s 50 day moving average is $25.88 and its 200 day moving average is $27.74. The company has a market capitalization of $206.18 million, a PE ratio of 29.89, a price-to-earnings-growth ratio of 4.32 and a beta of 0.68. Transcat has a 12-month low of $16.50 and a 12-month high of $34.18. The company has a current ratio of 2.32, a quick ratio of 1.64 and a debt-to-equity ratio of 0.52.
Transcat (NASDAQ:TRNS) last issued its earnings results on Wednesday, July 22nd. The scientific and technical instruments company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.14. The company had revenue of $38.90 million for the quarter, compared to the consensus estimate of $38.72 million. Transcat had a return on equity of 11.02% and a net margin of 4.21%. Equities research analysts predict that Transcat will post 0.83 earnings per share for the current year.
In related news, Director Gary J. Haseley bought 3,000 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was purchased at an average price of $25.20 per share, for a total transaction of $75,600.00. Following the acquisition, the director now owns 27,255 shares in the company, valued at $686,826. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 8.90% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the company. Marshall Wace North America L.P. boosted its holdings in shares of Transcat by 157.5% in the 1st quarter. Marshall Wace North America L.P. now owns 1,545 shares of the scientific and technical instruments company’s stock worth $36,000 after purchasing an additional 945 shares during the period. Citigroup Inc. boosted its holdings in Transcat by 305.3% during the 4th quarter. Citigroup Inc. now owns 1,386 shares of the scientific and technical instruments company’s stock valued at $44,000 after acquiring an additional 1,044 shares during the period. Royal Bank of Canada boosted its holdings in Transcat by 293.0% during the 1st quarter. Royal Bank of Canada now owns 1,792 shares of the scientific and technical instruments company’s stock valued at $48,000 after acquiring an additional 1,336 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in Transcat by 123.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,133 shares of the scientific and technical instruments company’s stock valued at $57,000 after acquiring an additional 1,180 shares during the period. Finally, SG Americas Securities LLC purchased a new position in Transcat during the 2nd quarter valued at $162,000. Hedge funds and other institutional investors own 69.36% of the company’s stock.
Transcat Company Profile
Transcat, Inc provides calibration and laboratory instrument services in North America and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.
Read More: Treasury Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.